Runny Nose
0 original drugs 0
Novel Drugs
13
Reformulations
0
Active Trials
1
Drug Targets
Runny Nose has 0 FDA-approved novel treatments across 1 drug target. Explore market leaders, treatments by mechanism, the clinical pipeline, and drug targets below.
Novel Runny Nose Drugs by Company (New molecular entities)
No novel drugs found for this indication.
Reformulations (13 drugs) Click to expand
Reformulations are FDA-approved versions of existing molecules in new dosage forms (e.g., oral solution vs tablet, extended-release vs immediate-release). They require a new NDA but use an already-proven active ingredient.
PHENYLEPHRINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE
Dr. Reddy's
T5 2025
SYMBICORT AEROSPHERE
AstraZeneca
EFFICACY 2023
BREZTRI AEROSPHERE
AstraZeneca
UNKNOWN 2020
IMMPHENTIV
Hikma
T7 2012
ASTEPRO
Viatris
T5 2008
ENTOCORT EC
PADAGIS US
T3 2001
FLOVENT DISKUS 250
GSK
T3 2000
FLOVENT DISKUS 50
GSK
T3 2000
FLOVENT DISKUS 100
GSK
T3 2000
ADVAIR DISKUS 500/50
GSK
T4 2000
ADVAIR DISKUS 100/50
GSK
T4 2000
ADVAIR DISKUS 250/50
GSK
T4 2000
RHINOCORT
AstraZeneca
T1 1994
Runny Nose Drug Targets
Molecular targets of approved and investigational Runny Nose drugs — 1 target tracked.
Generic Drugs (5 ANDA approved) Click to expand
Generic drugs contain the same active ingredient as the brand-name drug and are approved via ANDA (Abbreviated New Drug Application).
Drug Categories:
- Novel Drugs: NDA Type 1/2 (new molecular entity) or original BLA
- Reformulations: NDA Type 3/5 (new dosage form of existing molecule)
- Biosimilars: BLA-approved biologics highly similar to reference products
- Generics: ANDA-approved copies of small molecule drugs